SCHEMBL17199010

SCHEMBL17199010

N=C(N)NCCc1ccc(-c2ccccc2)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
RXFP1 Q9HBX9 1/20 0.50
CNR1 P21554 1/20 0.49
HIF1A Q16665 2/20 0.48
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
ST14 Q9Y5Y6 1/20 0.46
TAAR1 Q96RJ0 2/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
FFAR1 O14842 1/20 0.46
WDR5 P61964 1/20 0.46
MMP12 P39900 1/20 0.45
IL1RN P18510 1/20 0.44
ERAP2 Q6P179 1/20 0.44
ERAP1 Q9NZ08 1/20 0.44
ADAMTS5 Q9UNA0 1/20 0.44
FAAH O00519 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL28129406 0.98 MEN1 (0.49) MEN1KMT2ARXFP1CNR1HIF1A
[11C]Phenethylguanidine SCHEMBL28305964 0.95 NPC1 (0.53) MEN1KMT2ARXFP1HIF1ANPC1
SCHEMBL17198821 0.89 NPC1 (0.55) NPC1RAB9ASMN1; SMN2ST14TAAR1
[11C]Phenethylguanidine SCHEMBL837644 0.89 NPC1 (0.59) NPC1RAB9ASMN1; SMN2TAAR1LMNA
Hydrochloric Acid SCHEMBL28129397 0.87 NPC1 (0.53) NPC1RAB9ASMN1; SMN2ST14TAAR1
[11C]Phenethylguanidine SCHEMBL27117673 0.87 NPC1 (0.57) NPC1RAB9ASMN1; SMN2TAAR1LMNA
[11C]Phenethylguanidine SCHEMBL28129390 0.87 NPC1 (0.57) NPC1RAB9ASMN1; SMN2TAAR1LMNA
SCHEMBL324302 0.86 KDM4E (0.51) KMT2ANPC1RAB9ASMN1; SMN2ST14
SCHEMBL15139083 0.83 F10 (0.47) HIF1ALMNAFAAH
SCHEMBL17198935 0.81 ALDH1A1 (0.54) MEN1KMT2ANPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106458868-A Guanidine compounds and uses thereof 伊谬诺米特医疗有限公司 2017-02-22 CN claimed
CN-111848494-B Guanidine compounds and uses thereof 伊谬诺米特医疗有限公司 2023-08-01 CN disclosed
EP-3131877-B1 BIGUANIDE COMPOUNDS IMMUNOMET THERAPEUTICS INC (US) 2023-07-19 EP disclosed
CN-111848494-A Guanidine compounds and uses thereof 伊谬诺米特医疗有限公司 2020-10-30 CN disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 US disclosed
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF IMMUNOMET THERAPEUTICS INC. (US) 2017-03-16 US disclosed
CN-106458868-A Guanidine compounds and uses thereof 伊谬诺米特医疗有限公司 2017-02-22 CN disclosed
WO-2015160220-A1 GUANIDINE COMPOUNDS AND USE THEREOF HANALL BIOPHARMA CO., LTD. (KR) 2015-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170073331-A1 GUANIDINE COMPOUNDS AND USE THEREOF PC, TFAM, PCK2 MEN1 4540/4885KMT2A 1792/4885RXFP1 3310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.